JP2016504403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504403A5 JP2016504403A5 JP2015552095A JP2015552095A JP2016504403A5 JP 2016504403 A5 JP2016504403 A5 JP 2016504403A5 JP 2015552095 A JP2015552095 A JP 2015552095A JP 2015552095 A JP2015552095 A JP 2015552095A JP 2016504403 A5 JP2016504403 A5 JP 2016504403A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid solution
- solution pharmaceutical
- glyceryl
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000006104 solid solution Substances 0.000 claims 24
- 239000007788 liquid Substances 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 6
- 150000003626 triacylglycerols Chemical class 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 230000006020 chronic inflammation Effects 0.000 claims 3
- -1 glyceryl monostearidonic acid Chemical compound 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims 1
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 1
- FABAOYOFJNAVHB-RRABGKBLSA-N (e)-octadec-9-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC\C=C\CCCCCCCC(O)=O FABAOYOFJNAVHB-RRABGKBLSA-N 0.000 claims 1
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 claims 1
- ZXNAIPHYBVMMPY-KTKRTIGZSA-N 1-erucoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCC(O)CO ZXNAIPHYBVMMPY-KTKRTIGZSA-N 0.000 claims 1
- NVQGQHXFWUBOAU-KTKRTIGZSA-N 1-nervonoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)OCC(O)CO NVQGQHXFWUBOAU-KTKRTIGZSA-N 0.000 claims 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 1
- XSQSIJOKSPPKKS-UHFFFAOYSA-N 2,3-dihydroxypropyl docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)OCC(O)CO XSQSIJOKSPPKKS-UHFFFAOYSA-N 0.000 claims 1
- YBDMTIKLNFRWEB-UHFFFAOYSA-N 2,3-dihydroxypropyl icos-2-enoate Chemical compound CCCCCCCCCCCCCCCCCC=CC(=O)OCC(O)CO YBDMTIKLNFRWEB-UHFFFAOYSA-N 0.000 claims 1
- KFWNEOJLDXABRC-UHFFFAOYSA-N 2,3-dihydroxypropyl icosa-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OCC(O)CO KFWNEOJLDXABRC-UHFFFAOYSA-N 0.000 claims 1
- DMCMOFCRZHRTKH-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethanol Chemical compound CCOCCOCCO.CCOCCOCCO DMCMOFCRZHRTKH-UHFFFAOYSA-N 0.000 claims 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- JGYMUQRIGUVTCD-SYJLDBGTSA-N C(C(O)CO)CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O Chemical compound C(C(O)CO)CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O JGYMUQRIGUVTCD-SYJLDBGTSA-N 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010044210 PPAR-beta Proteins 0.000 claims 1
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 1
- 102000019280 Pancreatic lipases Human genes 0.000 claims 1
- 108050006759 Pancreatic lipases Proteins 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 claims 1
- 102000001424 Ryanodine receptors Human genes 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 229940033495 antimalarials Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003720 enoxolone Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- GGJRAQULURVTAJ-UHFFFAOYSA-N glyceryl monolinolenate Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-UHFFFAOYSA-N 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940049918 linoleate Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229940116369 pancreatic lipase Drugs 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- GGJRAQULURVTAJ-PDBXOOCHSA-N rac-1-alpha-linolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-PDBXOOCHSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752356P | 2013-01-14 | 2013-01-14 | |
| US61/752,356 | 2013-01-14 | ||
| US201361752309P | 2013-02-04 | 2013-02-04 | |
| US61/752,309 | 2013-02-04 | ||
| PCT/EP2014/050637 WO2014108573A1 (en) | 2013-01-14 | 2014-01-14 | Solid solution compositions and use in chronic inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504403A JP2016504403A (ja) | 2016-02-12 |
| JP2016504403A5 true JP2016504403A5 (https=) | 2017-02-16 |
| JP6389190B2 JP6389190B2 (ja) | 2018-09-12 |
Family
ID=50030251
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552096A Active JP6378694B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および激痛における使用 |
| JP2015552095A Active JP6389190B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および慢性炎症における使用 |
| JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
| JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
| JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
| JP2023045431A Active JP7748411B2 (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552096A Active JP6378694B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および激痛における使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
| JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
| JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
| JP2023045431A Active JP7748411B2 (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (6) | EP3858335A1 (https=) |
| JP (6) | JP6378694B2 (https=) |
| KR (6) | KR102235264B1 (https=) |
| CN (4) | CN104981253B (https=) |
| AU (4) | AU2014204737B2 (https=) |
| BR (3) | BR112015015891B1 (https=) |
| CA (3) | CA2897878A1 (https=) |
| ES (5) | ES2763352T3 (https=) |
| IL (5) | IL282123B (https=) |
| MX (3) | MX377340B (https=) |
| NZ (1) | NZ709486A (https=) |
| PL (1) | PL3795141T3 (https=) |
| RU (3) | RU2667977C2 (https=) |
| SG (4) | SG11201505241WA (https=) |
| WO (3) | WO2014108573A1 (https=) |
| ZA (3) | ZA201505002B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| ES2763352T3 (es) * | 2013-01-14 | 2020-05-28 | Infirst Healthcare Ltd | Composiciones de solución sólida y uso en inflamación crónica |
| PL3331568T3 (pl) * | 2015-08-07 | 2022-02-28 | Infirst Healthcare Limited | Kompozycje stałego roztworu dla nlpz |
| US10307388B2 (en) * | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
| AU2018354090B2 (en) | 2017-10-23 | 2024-10-24 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| EP3793560A4 (en) * | 2018-05-16 | 2022-03-23 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF AGING-RELATED CONDITIONS |
| AU2019274431B2 (en) | 2018-05-23 | 2025-03-13 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| CN108653273A (zh) * | 2018-07-13 | 2018-10-16 | 昆明医科大学第附属医院 | 青蒿素类化合物作为制备治疗贝赫切特病药物的应用 |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| EP3908374A4 (en) | 2019-01-09 | 2022-12-28 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES |
| WO2020180814A1 (en) | 2019-03-04 | 2020-09-10 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain |
| CN110251549B (zh) * | 2019-06-24 | 2021-12-03 | 浙江省肿瘤医院 | 淫羊藿总黄酮提取物在制备防治桥本甲状腺炎的药物中的应用 |
| EP3991722A4 (en) * | 2019-06-28 | 2022-10-05 | Jiangsu Hengrui Medicine Co., Ltd. | LIPID COMPOSITION WITH DELAYED RELEASE AND THEIR PROCESS OF PRODUCTION |
| DK3826630T3 (da) * | 2019-07-21 | 2022-09-26 | Scf Pharma Inc | Sammensætninger af cannabinoider med polyumættede fedtsyremonoglycerider og anvendelser heraf |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| WO2021158517A1 (en) * | 2020-02-03 | 2021-08-12 | Curemast, Inc. | Compositions and methods of use thereof for treatment of mastitis |
| RU2752764C1 (ru) * | 2020-12-14 | 2021-08-03 | Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") | Фармацевтическая композиция, обладающая противовоспалительным действием |
| EP4312978A2 (en) | 2021-03-27 | 2024-02-07 | TRX Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| EP4426130A1 (en) | 2021-11-03 | 2024-09-11 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
| CN114601843A (zh) * | 2022-03-22 | 2022-06-10 | 重庆医科大学附属第一医院 | 淫羊藿苷在制备治疗自身免疫性葡萄膜炎药物中的用途 |
| GB202208911D0 (en) * | 2022-06-17 | 2022-08-10 | Ravan Bio Limtied | Treatments |
| WO2024033521A1 (en) | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| US5143934A (en) * | 1990-11-21 | 1992-09-01 | A/S Dumex (Dumex Ltd.) | Method and composition for controlled delivery of biologically active agents |
| GB9613858D0 (en) * | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
| ATE265847T1 (de) * | 1997-07-29 | 2004-05-15 | Upjohn Co | Selbstemulgierbare formulierung enthaltend lipophile verbindungen |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| KR20020011985A (ko) * | 1999-05-07 | 2002-02-09 | 파르마솔 게엠베하 | 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법 |
| MXPA01011343A (es) * | 1999-05-07 | 2002-06-04 | Pharmasol Gmbh | Particulas de lipidos a base de mezclas de lipidos liquidos y solidos asi como procedimiento para su produccion. |
| EP1183014B1 (en) * | 1999-06-14 | 2003-10-08 | Cosmo S.p.A. | Controlled release and taste masking oral pharmaceutical compositions |
| ATE296091T1 (de) * | 1999-09-21 | 2005-06-15 | Skyepharma Canada Inc | Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
| US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
| JP3763567B2 (ja) * | 2001-01-19 | 2006-04-05 | 株式会社資生堂 | 化粧料 |
| US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| RU2319508C2 (ru) * | 2003-07-31 | 2008-03-20 | ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи | Диспергируемый препарат противовоспалительного агента |
| CA2540984C (en) * | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
| WO2005048927A2 (en) * | 2003-11-13 | 2005-06-02 | Combinatorx, Incorporated | Methods and reagents for the treatment of inflammatory disorders |
| EA013426B1 (ru) * | 2003-12-01 | 2010-04-30 | Рекордати Айэлэнд Лимитед | Фармацевтические композиции, содержащие лерканидипин |
| EP1750717B1 (en) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| CA2560613C (en) * | 2004-03-22 | 2015-11-24 | Solvay Pharmaceuticals Gmbh | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
| MX2007006183A (es) * | 2004-11-24 | 2007-09-11 | Merck & Co Inc | Formulaciones farmaceuticas liquidas y semisolidas para administracion oral de una amida sustituida. |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| KR20080023677A (ko) * | 2005-04-28 | 2008-03-14 | 갈레니카 테크놀로지 아베 | 지질상을 포함하는 약학적 투약 형태 |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| GB0704846D0 (en) * | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| RU2353349C2 (ru) * | 2007-04-18 | 2009-04-27 | Общество с ограниченной ответственностью "Фармацевтические технологии" | Средство для лечения болезней суставов |
| CN101129335B (zh) * | 2007-07-17 | 2010-09-22 | 浙江大学 | 一种纳米结构脂质载体给药系统的用途 |
| EP2310371B1 (fr) | 2008-05-26 | 2013-05-15 | Genfit | Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies |
| GB201018289D0 (en) * | 2010-10-29 | 2010-12-15 | Biocopea Ltd | Treatment of respiratory disorders |
| WO2012104654A1 (en) * | 2011-02-04 | 2012-08-09 | Biocopea Limited | Compositions and methods for treating cardiovascular diseases |
| WO2012127037A2 (en) * | 2011-03-24 | 2012-09-27 | Leo Pharma A/S | A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative |
| CN102793628B (zh) * | 2012-08-23 | 2014-07-02 | 东华大学 | 用于化妆品的液-固混合脂质纳米缓释系统及其制备方法 |
| ES2763352T3 (es) * | 2013-01-14 | 2020-05-28 | Infirst Healthcare Ltd | Composiciones de solución sólida y uso en inflamación crónica |
-
2014
- 2014-01-14 ES ES14702460T patent/ES2763352T3/es active Active
- 2014-01-14 EP EP21164383.8A patent/EP3858335A1/en active Pending
- 2014-01-14 CN CN201480006298.5A patent/CN104981253B/zh active Active
- 2014-01-14 BR BR112015015891-9A patent/BR112015015891B1/pt active IP Right Grant
- 2014-01-14 CA CA2897878A patent/CA2897878A1/en not_active Abandoned
- 2014-01-14 IL IL282123A patent/IL282123B/en unknown
- 2014-01-14 SG SG11201505241WA patent/SG11201505241WA/en unknown
- 2014-01-14 AU AU2014204737A patent/AU2014204737B2/en active Active
- 2014-01-14 CA CA2897884A patent/CA2897884C/en active Active
- 2014-01-14 NZ NZ709486A patent/NZ709486A/en unknown
- 2014-01-14 BR BR112015015898-6A patent/BR112015015898B1/pt active IP Right Grant
- 2014-01-14 IL IL295091A patent/IL295091B2/en unknown
- 2014-01-14 MX MX2015009104A patent/MX377340B/es active IP Right Grant
- 2014-01-14 KR KR1020157021076A patent/KR102235264B1/ko active Active
- 2014-01-14 AU AU2014204735A patent/AU2014204735B2/en active Active
- 2014-01-14 WO PCT/EP2014/050637 patent/WO2014108573A1/en not_active Ceased
- 2014-01-14 ES ES14703279T patent/ES2830033T3/es active Active
- 2014-01-14 KR KR1020157021075A patent/KR20150125648A/ko not_active Ceased
- 2014-01-14 JP JP2015552096A patent/JP6378694B2/ja active Active
- 2014-01-14 KR KR1020237002149A patent/KR20230017914A/ko not_active Ceased
- 2014-01-14 EP EP14703279.1A patent/EP2943223B1/en active Active
- 2014-01-14 CA CA2898000A patent/CA2898000A1/en not_active Abandoned
- 2014-01-14 MX MX2015009105A patent/MX379193B/es unknown
- 2014-01-14 EP EP14702460.8A patent/EP2925367B1/en active Active
- 2014-01-14 KR KR1020217040230A patent/KR102491426B1/ko active Active
- 2014-01-14 CN CN201480006216.7A patent/CN104968368B/zh active Active
- 2014-01-14 ES ES20192758T patent/ES3041421T3/es active Active
- 2014-01-14 EP EP14701930.1A patent/EP2943222B1/en active Active
- 2014-01-14 MX MX2015009106A patent/MX377877B/es unknown
- 2014-01-14 EP EP19188174.7A patent/EP3578172B1/en active Active
- 2014-01-14 RU RU2015134142A patent/RU2667977C2/ru active IP Right Revival
- 2014-01-14 KR KR1020217009229A patent/KR102338569B1/ko active Active
- 2014-01-14 KR KR1020157021073A patent/KR102252574B1/ko active Active
- 2014-01-14 JP JP2015552095A patent/JP6389190B2/ja active Active
- 2014-01-14 SG SG11201505249VA patent/SG11201505249VA/en unknown
- 2014-01-14 CN CN201480006940.XA patent/CN105007947B/zh active Active
- 2014-01-14 ES ES14701930T patent/ES2829904T3/es active Active
- 2014-01-14 JP JP2015552094A patent/JP6505607B2/ja active Active
- 2014-01-14 WO PCT/EP2014/050636 patent/WO2014108572A1/en not_active Ceased
- 2014-01-14 EP EP20192758.9A patent/EP3795141B1/en active Active
- 2014-01-14 BR BR112015015858-7A patent/BR112015015858B1/pt active IP Right Grant
- 2014-01-14 SG SG10201704472QA patent/SG10201704472QA/en unknown
- 2014-01-14 PL PL20192758.9T patent/PL3795141T3/pl unknown
- 2014-01-14 RU RU2015134141A patent/RU2675241C2/ru active IP Right Revival
- 2014-01-14 RU RU2015134143A patent/RU2674982C2/ru active IP Right Revival
- 2014-01-14 AU AU2014204734A patent/AU2014204734B2/en active Active
- 2014-01-14 WO PCT/EP2014/050638 patent/WO2014108574A1/en not_active Ceased
- 2014-01-14 CN CN201910070081.5A patent/CN109549927B/zh active Active
- 2014-01-14 ES ES19188174T patent/ES2875824T3/es active Active
- 2014-01-14 SG SG11201505247TA patent/SG11201505247TA/en unknown
-
2015
- 2015-07-13 ZA ZA2015/05002A patent/ZA201505002B/en unknown
- 2015-07-13 ZA ZA2015/05003A patent/ZA201505003B/en unknown
- 2015-07-13 ZA ZA2015/05004A patent/ZA201505004B/en unknown
- 2015-07-14 IL IL239923A patent/IL239923A0/en unknown
- 2015-07-14 IL IL239924A patent/IL239924A0/en unknown
- 2015-07-14 IL IL239922A patent/IL239922B/en active IP Right Grant
-
2016
- 2016-11-11 AU AU2016256804A patent/AU2016256804B2/en active Active
-
2019
- 2019-03-27 JP JP2019061720A patent/JP2019116498A/ja active Pending
-
2021
- 2021-08-27 JP JP2021139210A patent/JP7250865B2/ja active Active
-
2023
- 2023-03-22 JP JP2023045431A patent/JP7748411B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504403A5 (https=) | ||
| JP2016508155A5 (https=) | ||
| JP2016505625A5 (https=) | ||
| JP2016506941A5 (https=) | ||
| RU2015134141A (ru) | Композиции твердых растворов и их применение при хроническом воспалении | |
| JP2016504401A5 (https=) | ||
| AR084639A1 (es) | Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| JP2018526351A5 (https=) | ||
| UY33044A (es) | Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos | |
| JP2016531113A5 (https=) | ||
| EP2552203A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| JP2016532667A5 (https=) | ||
| EA201100863A1 (ru) | Фармацевтическая композиция, включающая диклофенак и сложный эфир гидроксижирной кислоты и полиоксиалкилена | |
| UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
| JP2016511753A5 (https=) | ||
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| JP2014509655A5 (https=) | ||
| JP2015506363A5 (https=) | ||
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| MX383762B (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k |